Company Overview of Coherus Biosciences Inc
Coherus Biosciences Inc., a biopharmaceutical company, engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It serves customers globally. The company has a strategic collaboration with Daiichi Sankyo. Coherus Biosciences Inc. was founded in 2010 and is based in Redwood City, California.
201 Redwood Shores Parkway
Redwood City, CA 94065
Founded in 2010
Key Executives for Coherus Biosciences Inc
Senior Vice President of Inflammatory Diseases
Senior Vice President of Oncology
Compensation as of Fiscal Year 2014.
Coherus Biosciences Inc Key Developments
Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 in Chronic Plaque Psoriasis (RaPsOdy)
Jul 16 14
Coherus BioSciences Inc. announced the start of its Phase 3 trial of CHS-0214, a proposed biosimilar of etanercept (Enbrel(R)), in chronic plaque psoriasis (the RaPsOdy trial). This announcement follows the recent initiation of a Phase 3 trial of CHS-0214 in rheumatoid arthritis. The Phase 3 psoriasis trial is a 48-week, randomized, double-blind, active-control, parallel-group, multicenter, global study in subjects with active, chronic plaque psoriasis who are naïve to systemic biologic therapy. The study will seek to demonstrate biosimilarity between CHS-0214 and Enbrel(R) in terms of efficacy, safety and immunogenicity. The primary efficacy endpoint is based on percent improvement in the Psoriasis Area and Severity Index (PASI) at 12 weeks.
Coherus BioSciences, Inc. Appoints V. Bryan Lawlis to Board of Directors
Jul 9 14
Coherus BioSciences Inc. announced the appointment of V. Bryan Lawlis to its Board of Directors.
Coherus Biosciences Inc Announces Initiation of Phase 3 Trial of CHS-0214 (Investigational Etanercept Biosimilar) in Rheumatoid Arthritis
Jun 23 14
Coherus Biosciences Inc. announced the start of its Phase 3 trial of CHS-0214, an investigational etanercept biosimilar, in rheumatoid arthritis (RA). The Phase 3 trial is a randomized, double-blind, active-control, parallel-group, multicenter, global study in subjects with active RA who have demonstrated an inadequate response to methotrexate. The primary endpoint is ACR 20 at 24 weeks. The initiation of a CHS-0214 Phase 3 study is an important event for RA patients. This trial of biosimilar etanercept advances its goal to expand access to this life-changing medication for patients with RA. This trial marks transition to a Phase 3 company. Coherus brings complementary capabilities with the potential to support accelerated entry into the biosimilar market for Baxter.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries